Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee

Carmina, Enrico; Azziz, Ricardo; Bergfeld, Wilma F.; Escobar-Morreale, Héctor F.; Futterweit, Walter; Huddleston, Heather G.; Løbo, Rogerio A.; Olsen, Elise A.

doi:10.1210/jc.2018-02548

Cited by 85 publications

(100 citation statements)

References 133 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, this study did not report on clinical symptoms of hyperandrogenism [72]. It is also unclear whether there is a link between hyperprolactinaemia and female pattern hair loss [73]. It is possible that PRL exacerbates hyperandrogenism in clinically predisposed women, such as those with PCOS [51] but further studies are needed on this topic.…”

Section: Womenmentioning

confidence: 86%

Hyperprolactinaemia

Samperi

Lithgow

Karavitaki

2019

JCM

View full text Add to dashboard Cite

Hyperprolactinaemia is one of the most common problems in clinical endocrinology. It relates with various aetiologies (physiological, pharmacological, pathological), the clarification of which requires careful history taking and clinical assessment. Analytical issues (presence of macroprolactin or of the hook effect) need to be taken into account when interpreting the prolactin values. Medications and sellar/parasellar masses (prolactin secreting or acting through "stalk effect") are the most common causes of pathological hyperprolactinaemia. Hypogonadism and galactorrhoea are well-recognized manifestations of prolactin excess, although its implications on bone health, metabolism and immune system are also expanding. Treatment mainly aims at restoration and maintenance of normal gonadal function/fertility, and prevention of osteoporosis; further specific management strategies depend on the underlying cause. In this review, we provide an update on the diagnostic and management approaches for the patient with hyperprolactinaemia and on the current data looking at the impact of high prolactin on metabolism, cardiovascular and immune systems.

show abstract

Section: Womenmentioning

confidence: 86%

Hyperprolactinaemia

Samperi

Lithgow

Karavitaki

2019

JCM

View full text Add to dashboard Cite

show abstract

“…Механізми такого різнобічного впливу андрогенів на волосся є не до кінця зрозумілими; основною теорією є вплив андрогенів через матрикс і дермальний сосочок, який призводить до активації сигнальних шляхів (Wnt, трансформуючий фактор росту ß (ТФР-ß), що регулюють процеси росту та апоптозу [12,21,22]. Ймовірно, відповідь клітин волосяних фолікулів різних ділянок шкіри на вплив андрогенів є генетично детермінованою [2,23].…”

Section: ранній анаген анагенunclassified

“…Перед початком пошуку системних причин необхідно попередньо визначити різновид алопеції на основі даних анамнезу і зовнішніх проявів (рубцева/нерубцева -різновид нерубцевої). Також важливо усвідомлювати, що найбільш розповсюджена форма алопеції -АГА в певні періоди часу може сполучатись з іншою розповсюдженою патологією -телогеновим випадінням волосся (ТВВ), оскільки цей факт визначає терапевтичні підходи та їх результати [26,27].…”

Section: алопеціяunclassified

“…Metabolism був опублікований звіт Мультидисциплінарного комітету з гіперандрогенії і синдрому полікістозних яєчників (СПКЯ) щодо даного різновиду алопеції в жінок. Потреба в створенні цього документа була обумовлена чис ленними суперечностями стосовно поняття АГА у жінок (втрата волосся за жіночим типом (ВВЖТ) female pattern hair loss), розгляду його в контексті андроген-асоційованої патології, а також об'єму обстеження і менеджменту [27].…”

Section: втрата волосся за жіночим типом/ андрогенетична алопеція у чunclassified

See 1 more Smart Citation

Androgen-associated and androgen-independent causes of alopecia and acne in women. Literature review

Сидорова

Тутченко

Бурка

et al. 2020

View full text Add to dashboard Cite

This article refers to the issues of alopecia and acne pathogenesis: anatomy of hair and sebaceous glands, biological factors affecting the stages of hair development and function of sebaceous glands. Alopecia is divided into two large groups: scaring and non-scaring alopecia, the later is represented by alopecia areata, telogen effluvium, and female pattern hair loss/androgenetic alopecia (FPHL/AGA). Before starting the search for systemic causes it is necessary to predetermine the type of alopecia on the basis of medical history and external manifestations. FPHL /AGA as a most common form of alopecia can often coexist with another common pathology – telogen effluvium, this fact determines therapeutic approaches and their results.Main pathogenetic mechanisms, approaches to differential diagnostics and treatment of the main specified types of non-scarring alopecia are reviewed. FPHL/AGA is a main type of alopecia which is often referred to gynecologists/endocrinologists. It is now regarded a multifactorial pathology with the involvement of a genetic component, androgen receptor gene expression, dihydrotestosterone synthesis and local low grade inflammation specifics. FPHL/AGA can be with and without hyperandrogenism, in both cases it can be accompanied by an increased risk of metabolic syndrome. In case of FPHL/AGA with hyperandrogenism the success of treatment depends on the consistent coordinated work of gynecologist/endocrinologist and dermatologist/trichologist, which allows combining systemic and local therapy in a timely manner.Also contemporary views on the acne pathogenesis are reviewed. Given the complex nature of acne its therapy is also complex and stepwise. According to current clinical guidelines and recent studies of the microbial component of acne pathogenesis the following conclusions are formulated. Patients with acne require assessment of androgen status, determination of the hyperandrogenism source, including evaluation of tissue androgens; phenotype of the syndrome and cardio-metabolic risks should be determined in patients with polycystic ovary syndrome; it is advisable to determine antimicrobial susceptibility of pathogens isolated from the inflamed pilosebaceous unit if acne form requires the local or systemic antibacterial therapy.

show abstract

“…The prevalence increases from 12% for women between 20 and 29 years of age, to more than 50% for women over the age of 80 years 14 . According to Carmina E et al, FPHL is seen in approximately 20%‐30% of the patients with PCOS 15 …”

Section: Introductionmentioning

confidence: 99%

Evaluation of efficacy of QR 678 and QR678 neo hair growth factor formulation for the treatment of female pattern alopecia in patients with PCOS—A prospective study

Kapoor¹,

Shome²,

Doshi³

et al. 2020

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Background Hair is an essential identity of women. Femininity, sexuality, attractiveness, and personality are symbolically linked to a woman’s hair. Female pattern hair loss is found in 20%‐30% of patients with polycystic ovary syndrome (PCOS). Aim The aim of the present study was to evaluate the efficacy of QR678® and QR678 Neo® therapy in the treatment of female alopecia with PCOS. Method A total of 20 females diagnosed with PCOS in the age 25‐50 years, with complaints of female pattern alopecia with Ludwig, grades I, and II were selected for the study. At each visit, 1.5 ml solution of QR678® was injected in the scalp skin of patients. A total of eight sessions were performed at an interval of 3 week each. All the patients were evaluated with standard global photography at baseline, 4th and 8th session, and 2 months after 8th session. Result Marked improvement was seen in the global photographic assessment score (mean = 8) which was maintained for over 1 year. In videomicroscopic assessment, after four sessions the patients had 8.07 fewer vellus hair, 6.07 more terminal hair, and average hair shaft diameter was 0.82 μm wider. After eight sessions, they had 11.66 fewer vellus hair, 13.77 more terminal hair, and hair shaft diameter was 2.86 μm wider than at baseline. Conclusion Intra‐dermal injections of QR 678® hair growth factor formulation is an effective option for female pattern alopecia with PCOS. This is the first of its kind study using QR678® and QR678 Neo® in PCOS patients.

show abstract

Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee

Cited by 85 publications

References 133 publications

Hyperprolactinaemia

Hyperprolactinaemia

Androgen-associated and androgen-independent causes of alopecia and acne in women. Literature review

Evaluation of efficacy of QR 678 and QR678 neo hair growth factor formulation for the treatment of female pattern alopecia in patients with PCOS—A prospective study

Contact Info

Product

Resources

About